Takaisin Tulosta

Parkinsonin taudin edenneen vaiheen ongelmat

Lisätietoa aiheesta
Kyösti Sotaniemi
1.6.2015

Motoriset komplikaatiot

Yksi- ja kaksivaiheinen dyskinesia ja dystonia

Lääkevaikutuksen vaihtelu

Dopaminergisen vaikutuksen tasoittaminen

Kirjallisuutta

  1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009;72:S1-136 «PMID: 19470958»PubMed
  2. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2-9; discussion S9-11 «PMID: 10762127»PubMed
  3. Fahn S, Ford B. Medical treatment of Parkinson’s disease and its complications. Kirjassa Neurological therapeutics: principles and practice. Noseworthy JH (toim.). Informa Healthcare, Oxon, 2006: 2766-802
  4. Fox SH, Lang AE. Levodopa-related motor complications--phenomenology. Mov Disord 2008;23 Suppl 3:S509-14 «PMID: 18781677»PubMed
  5. Tolosa EW, Katzenschlager R. Pharmacological management of Parkinson’s disease. Kirjassa: Parkinson’s disease and movement disorders. Jankovic J, Tolosa E (toim.), Lippincott Williams & Wilkins, Philadelphia, 2007:110-45
  6. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2008;23 Suppl 3:S599-612 «PMID: 18781681»PubMed
  7. Obeso JA, Rodriguez-Oroz M, Marin C ym. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62:S17-30 «PMID: 14718677»PubMed
  8. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47:S167-76; discussion S176-8 «PMID: 10762145»PubMed
  9. Rascol O, Goetz C, Koller W ym. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98 «PMID: 12047983»PubMed